Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03903068
Other study ID # 10000001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2019
Est. completion date October 30, 2020

Study information

Verified date August 2019
Source Xuanwu Hospital, Beijing
Contact Haiqing Song, doctor
Phone 86-13701390976
Email songhq@xwhosp.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-stroke depression (PSD) is one of the most common complications after stroke, with a high prevalence. PSD can affect prognosis and rehabilitation of stroke, increase risks of mortality and suicide, and escalate the economic burden on individuals and society. Studies have shown that transcranial alternating current stimulation (tACS) can also be used to treat depression, insomnia and anxiety. So far, this stimulator has been approved by FDA. However, there have not been any reports on the use of tACS in the treatment of depression and PSD in China. In this trial, the efficacy and safety of the tACS will be assessed with the rigor methodology manner.


Description:

Patients with post-stroke depression (PSD) have more dysfunction, poorer recovery outcomes, and higher morbidity and mortality in the first year after stroke onset than those patients without stroke. Some therapeutic methods have shown to be effective for PSD, including antidepressants, non-drug interventions, and combination therapies. However, pharmacological agents not only show unwanted side effects, including nausea, diarrhea, fatigue, and dizziness, but also produce high risk of hemorrhagic complications and stroke. Therefore, in addition to antidepressants treating PSD, non-drug interventions have been proposed to treat PSD. Until now, there are various physical techniques, including transcranial magnetic stimulation, vagus nerve stimulation, transcranial direct current stimulation, transcranial ultrasonic stimulation, etc. Previous studies have shown that transcranial alternating current stimulation (tACS) is commonly used to relieve pain, and has also been used to treat conditions such as transient tic disorder and cluster headaches. In the brain, there are specific opioid receptors which are not independent, and they work together with the electro analgesic system. Patients treated for chronic pain had lower levels of endorphins in their cerebrospinal fluid. Theoretically, using tACS can alleviate pain was caused by electrical stimulation to activate the brain's pain system (anti-nociceptive system), led to the beta-endorphin, serotonin and norepinephrine release.

Therefore, the study is expected to verify the effect of Transcranial Alternating Current Stimulation on patients with PSD in China and preliminarily explore the variations of gamma and beta-oscillations and cognitive function for the intervention of PSD utilized by it.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date October 30, 2020
Est. primary completion date August 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. A diagnosis of PSD is based on the "Depressive disorder due to another medical condition" of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V);

2. Age 18-70 years old, gender is not limited;

3. Right-handed;

4. More than 6 months after the onset of stroke;

5. The duration of depressive disorder persists for more than two weeks;

6. Having the Hamilton Depression Rating Scale 17-Item (HAMD-17) scores higher than 17 at baseline;

7. Absence of psychiatric disorder or family history of psychosis before stroke;

8. Has never taken antidepressants before enrollment;

9. Having the level of audiovisual for examinations required for the study;

10. Providing signed informed consent.

Exclusion Criteria:

1. Patients with life expectancy < 6 months;

2. Severe or unstable organic diseases;

3. Acute brain injury and infection;

4. The impaired skin integrity at the electrode placement site or skin allergic to electrode gel or adhesive;

5. Active current suicidal intent or plan as shown by a score of = 3 on the suicide item of HAMD-17;

6. Current participation in any other clinical trial,;

7. Prior exposure to all kinds of neuromodulation treatments (including electroconvulsive therapy, TMS, tDCS, etc);

8. Prior exposure to any implanted device in body (including a cochlear implant, cardiac pacemaker, an implanted device or metal in the brain);

9. A history of brain organic diseases (including seizures, hydrocephalus, and brain tumors);

10. Any situations the investigators believe that they are not suitable for this study.

Study Design


Intervention

Device:
NEXALIN ADI AC stimulator
When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
Pseudo-stimulator
When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.

Locations

Country Name City State
China Xuanwu Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

References & Publications (2)

Gabis L, Shklar B, Baruch YK, Raz R, Gabis E, Geva D. Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial. J Rehabil Med. 2009 Mar;41(4):256-61. doi: 10.2340/16501977-0315. — View Citation

Shen X, Liu M, Cheng Y, Jia C, Pan X, Gou Q, Liu X, Cao H, Zhang L. Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression: A systematic review and meta-analysis of randomized controlled clinical trials. J Affect Disord. 2017 Mar 15;211:65-74. doi: 10.1016/j.jad.2016.12.058. Epub 2017 Jan 10. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the proportion of participants having an improvement at week 8 the proportion of participants having an improvement at week 8, which includes response per the Hamilton Depression Rating Scale 17-Item (HAMD-17) defined as a = 50% reduction from the baseline or clinical recovery (score = 7). week 8
Secondary The proportions of participants achieve an improvement in neurological function The improvement will be decided by a reduction of = 50% or the total score of 0-1 in the National Institute of Health Stroke Scale (NIHSS) score (ranging from 0 to 42, higher scores indicate a more severe neurological deficit) weeks 4 and 8
Secondary The proportions of participants achieve an improvement in independence measured by a modified Rankin Scale (mRS) over the trial (scores on this scale range from 0 to 6, with higher scores indicating more significant disability), and the improvement is defined as 0, 1, and 2 in mRS. weeks 4 and 8
Secondary The proportions of participants with a Barthel Index (BI) score of = 90 the Barthel Index (BI) score is used to assess the activities of daily living (ranging from 0 to 100, higher scores indicate increased independence) weeks 4 and 8
Secondary The proportions of participants having severity levels the Clinical Global Impression-Severity (CGI-S) is a 7-point scale ranging from 1 being "normal, not at all ill" to 7 being "among the most extremely ill patients" weeks 4 and 8
Secondary CGI-Improvement (CGI-I) The proportions of participants have improvements of 1, 2, and 3 in the CGI-Improvement. weeks 4 and 8
Secondary the Hamilton Anxiety Rating Scale (HAMA) The changes of participants on anxiety symptoms weeks 4 and 8
Secondary the Mini-Mental State Examination (MMSE) The changes of participants on cognitive function assessed by MMSE weeks 4 and 8
Secondary the Montreal Cognitive Assessment (MoCA) The changes of participants on cognitive function weeks 4 and 8
Secondary the proportion of participants having an improvement at week 4 the proportion of participants having an improvement at week 4, which includes response per the Hamilton Depression Rating Scale 17-Item (HAMD-17) defined as a = 50% reduction from the baseline or clinical recovery (score = 7). week 4
Secondary the changes of beta-and gamma-oscillations at weeks 4 and 8 assessing the resting-state high-density EEG (rsHEEG) by utilizing a 128 channel EEG system (Geodesic EEG system 400, Electrical Geodesics, Inc., OR, USA) at baseline, week 4, and week 8. weeks 4 and 8
Secondary the variations of cognitive status at weeks 4 and 8 to measure cognitive status of PSD by the repeatable battery for the assessment of neuropsychological status (RBANS) at baseline, week 4, and week 8. weeks 4 and 8
Secondary the proportions of participants have an epileptic seizure at weeks 4 and 8 Electroencephalogram (EEG) of all patients will be recorded at baseline, week 4, and week 8. and the epileptic seizure will be verified by two independent experienced neurologists based on EEG activity and clinical manifestations. weeks 4 and 8
Secondary the proportions of participants who have symptoms in the treatment-emergent symptom scale (TESS) at weeks 4 and 8 TESS will be assessed at weeks 4 and 8 weeks 4 and 8
See also
  Status Clinical Trial Phase
Recruiting NCT05612659 - Developing an EEG Probe for Studying and Modulating Cognitive Control N/A
Completed NCT04093843 - TMS for Post Stroke Depression N/A
Recruiting NCT05516680 - Effects and Central Mechanism of Electroacupuncture and MRI-navigated rTMS for PSD N/A
Recruiting NCT04876066 - Use of Transmucosal Ketamine in Post Stroke Depression Phase 1
Recruiting NCT03159351 - The Antidepressant Effects of rTMS After Ischemic Stroke N/A
Recruiting NCT03864484 - iPad Application-based Intervention for Post-stroke Depression N/A
Recruiting NCT05310175 - Efficacy of Acupuncture at Acupoints Group Around the Base of Skull for Post-Stroke Depression N/A
Completed NCT03639259 - Emotional and Cognitive Determinants of Post-stroke Fatigue
Completed NCT02472613 - Acupuncture for Ischemic Post-stroke Depression N/A
Completed NCT04008719 - ATtention Test and Executive Functions After STroke to Predict Depression. N/A
Recruiting NCT05241782 - The Effect of Auricular Acupressure on the Improvement of Anxiousness, Depression and Heart Rate Variability in Stroke Patients N/A
Withdrawn NCT03761303 - rTMS as an add-on Therapy in Patients With Post-stroke Depression N/A
Completed NCT04318951 - Impact of Intensive Social Interaction on Post-Stroke Depression in Individuals With Aphasia N/A
Completed NCT04560413 - Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients
Recruiting NCT05187975 - Integrated Rehabilitation in Treating Post-stroke Depression N/A
Completed NCT06157333 - Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation on Patients With Post-stroke Depression N/A
Completed NCT03829397 - To Investigate the Correlation of Stroke Patients and Demoralized
Recruiting NCT03256305 - A Study of rTMS Personalized Precision Treatment of Post-stroke Depression N/A
Recruiting NCT03789994 - Affective Touching on Poststroke Depression N/A
Completed NCT05932550 - Safety of Maraviroc for Post-stroke Depression Phase 2